西米达结合剂作为多向抗癌剂 - - 一个全面的审查
R S Remya1, N Ramalakshmi1, M G Safiya Aaliya1
1Department of Pharmaceutical Chemistry, C.L. Baid Metha College of Pharmacy, Thoraipakkam, Chennai, India.
本综述探讨了胺混合物作为有前途的抗癌药物,解决癌症治疗中的耐药性问题. 这些化合物显示出作为针对各种癌症的向治疗的潜力.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 癌症是全球主要的死亡原因,耐药性限制了目前的治疗疗效.
- 多种药物耐药性在临床癌症治疗中构成了重大挑战.
- 西米达衍生物正在研究它们的治疗潜力.
研究的目的:
- 综合审查本齐米达混合物作为潜在的抗癌药物.
- 分析有助于抗癌活性的结构特征.
- 为设计新的向癌症疗法提供见解.
主要方法:
- 系统的文献审查大约70个研究作品.
- 对具有各种异环环的本齐米达杂交物的研究分析.
- 对抗癌症功效的结构-活性关系的检查.
主要成果:
- 西米达混合物显示出作为抗癌剂的显著潜力.
- 这些化合物对一系列癌症类型表现出活性.
- 结构性修改会影响它们的向抗癌效果.
结论:
- 西米达混合物代表了一类有前途的向抗癌药物.
- 它们的多方面的作用机制比传统疗法具有优势.
- 本综述是开发基于本齐米达的新型癌症药物的指南.
更多相关视频
11:14Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Phase II Conjugation Reactions: Overview
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
